Nucleus RadioPharma

NUCLEUS RADIOPHARMAManage supplier listing

Radiopharmaceutical CDMO manufacturing, distribution-tracking, and regulatory-compliance exhaust data — as a cGMP contract manufacturer with a regional distribution model, real-time distribution tracking, and isotope supply redundancy across a growing multi-facility network (Rochester, MN plus a planned Pennsylvania facility), Nucleus RadioPharma's production and logistics systems generate structured records of dose/vial production volumes by facility, real-time shipment/distribution tracking data, isotope supply-chain redundancy routing, and cGMP quality/regulatory compliance records (21 CFR 211, EU Annex 1, ISO 13408) across its client radiopharmaceutical and theranostics programs.

Open buyer room →

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Nucleus RadioPharma and files the sample in your catalog — private to you.

Start 7-day trialNothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry: Life Sciences Tools & ServicesPharmaceuticals
Instruments: equities
Categories

Dataset card

Type: not stated
Format: Tabular (production-volume, distribution-tracking, and regulatory/QC compliance records)
Volume: ~10K dose-production records/year currently at the Rochester, MN facility, scaling toward 40-50K vials/year there, with a planned Pennsylvania facility targeting ~450K vials/year — implying production-record volume could grow from ~10K to 500K+ records/year within a few years.
Users: N/A — B2B CDMO serving pharma/biotech client programs, not a registered-user platform; est. low tens of active client programs (low confidence, inferred from 54-employee scale and early-stage facility capacity).
History: 5 years
Update frequency: not stated
Growth: Active — explicit capacity expansion plans (Rochester facility growing from ~10K to 40-50K vials/year; new Pennsylvania facility planned at ~450K vials/year) backed by a ~$112M venture funding round.
Launched: Est. ~2021-2022 (precise founding date not stated on the page; the company's small 54-person headcount relative to its $112M raise and early facility-buildout stage are consistent with a radiopharmaceutical CDMO founded in the early-2020s boom in theranostics manufacturing) — low confidence.
Delivery: not stated
Entity mapping: not stated
Sample: not stated
Point-in-time: not stated
Licence: not stated

supplier index read from their site